Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$155MLATEST DEAL AMOUNT
Developer of human monoclonal antibody therapeutics. The company develops technologies that produce stable and functional binding molecules enabling the discovery of human antibodies against therapeutic target.